Progen Confirms Long-Acting Potential of Oral Obesity Treatment in Phase 1a Trial

"RPG-102" Shows Over 150% Systemic Exposure Compared to Same-Dose Injection
Safety and Tolerability Confirmed; Phase 1b Clinical Trial for Obese Patients Planned After Additional Cohort Study

Progen, a company specializing in new drug development, announced on July 16, 2026, that it has released initial results from a Phase 1a clinical trial of RPG-102 (RT-114), an orally administered dual-action GLP-1/GLP-2 obesity treatment currently being co-developed with U.S.-based Rani Therapeutics. The clinical study results were made public on July 15 (U.S. local time).

RPG-102 is a candidate that combines Progen’s dual-acting GLP-1/GLP-2 therapy “PG-102” with Rani Therapeutics’ oral drug delivery platform “RaniPill®.”

Progen panorama. Progen

This Phase 1a clinical trial is an open-label, single-dose study involving 30 healthy adults. Participants received either an oral dose of 12 mg RPG-102 or a subcutaneous injection of PG-102 at the same dosage.

According to the initial pharmacokinetic (PK) analysis, RPG-102 demonstrated more than 150% systemic exposure compared to the same dosage delivered by subcutaneous injection. The drug’s elimination half-life was similar in both groups: 5.6 days in the oral administration group and 5.3 days in the subcutaneous injection group.

Both safety and tolerability were confirmed. No serious adverse events were reported in either group, and only mild adverse events—such as nausea, vomiting, and diarrhea, commonly seen with GLP-1 therapies—were observed. No adverse events associated with the RaniPill® capsule itself were reported.

Progen and Rani Therapeutics plan to conduct an additional cohort study with 15 healthy adults, administering a 24 mg dose of RPG-102, to further evaluate the pharmacokinetic properties between oral and subcutaneous administration. The collected data will be used to determine dosage and design for a repeat-dose Phase 1b clinical trial targeting obese patients.

Kim Jonggyun, CEO of Progen, said, “These results are meaningful in that they confirm the potential for developing a long-acting oral obesity treatment in humans. We plan to continue development through further clinical trials and also pursue global commercialization.”

This content was produced with the assistance of AI translation services.